Who
PureTech Health plc
10% owner
Company insider
Files Form 4 as: 10% owner, Seaport Therapeutics; 10% owner, Gelesis Holdings.
In numbers
- Trades disclosed
- 19
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 1 May 2023
- Last trade
- 4 May 2026
- Last filed
- 6 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 May 2026filed 6 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —12,736,014 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —2,681,265 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —965,255 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000,000 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —8,421,052 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,031,578 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —40,000,000 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —8,421,052 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —3,031,578 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —12,736,014 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —2,681,265 | filing |
| 4 May 2026filed 6 May 2026 | SPTX Seaport TherapeuticsBiotechnology | SEC FORM 4 Code C | —965,255 | filing |
| 20 Sep 2023filed 21 Sep 2023 | Gelesis Holdingsoption or derivative | SEC FORM 4 Code P | — | filing |
| 26 May 2023filed 31 May 2023 | Gelesis Holdingsoption or derivative | SEC FORM 4 Code P | $15.10T43,133,803 at $350,000.00 | filing |
| 26 May 2023filed 31 May 2023 | Gelesis Holdingsoption or derivative | SEC FORM 4 Code P | — | filing |
| 1 May 2023filed 3 May 2023 | Gelesis Holdingsoption or derivative | SEC FORM 4 Code P | $25.00T5,000,000 at $5,000,000.00 | filing |
| 1 May 2023filed 3 May 2023 | Gelesis Holdingsoption or derivative | SEC FORM 4 Code P | $4.00T2,000,000 at $2,000,000.00 | filing |
| 1 May 2023filed 3 May 2023 | Gelesis Holdingsoption or derivative | SEC FORM 4 Code P | —23,688,047 | filing |
| 1 May 2023filed 3 May 2023 | Gelesis Holdingsoption or derivative | SEC FORM 4 Code P | —192,307,692 | filing |
News
PureTech Health plc: PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026finanznachrichten.de · 19 Oct 2026PureTech Health plc (OTCMKTS:PTCHF) Sees Large Drop in Short Interestdailypolitical.com · 13 Oct 2026
2 headlines in the last 90 days name PureTech Health plc; no company of theirs resolves to a name we track.
Sectors
No trade we could place in a sector.